Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMNAFG1)

Drug Name
Olomoucine Drug Info
Synonyms
olomoucine; 101622-51-9; 4erk; UNII-6A839B2HYS; 2-(2-Hydroxyethylamino)-6-benzylamino-9-methylpurine; 6A839B2HYS; CHEMBL280074; 2-{[6-(benzylamino)-9-methyl-9h-purin-2-yl]amino}ethanol; 6-Benzylamino-2-(2-hydroxyethylamino)-9-methylpurine; 6-(Benzylamino)-2-(2-hydroxyethylamino)-9-methylpurine; Ethanol,2-[[9-methyl-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-; OLO; 2-(Hydroxyethylamino)-6-benzylamino-9-methylpurine; 6-Benylamino-2-(2-hydroxyethylamino)-9-methylpurine
Cross-matching ID
PubChem CID
4592
ChEBI ID
CHEMBL280074
CAS Number
CAS 101622-51-9
TTD Drug ID
D00BPA

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
DNA replication 2.08 0.00e+0 34/36 (94.44%) PCNA;MCM7;RFC5;...
Mismatch repair 2.04 0.00e+0 22/23 (95.65%) PCNA;RFC5;MSH2;...
Ribosome 1.86 1.32e-2 113/158 (71.52%) MRPS16;MRPL33;RPS5;...
Intestinal immune network for IgA production 1.83 1.59e-2 38/48 (79.17%) CD40;IL15;HLA-DRB1;...
Allograft rejection 1.82 1.43e-2 32/38 (84.21%) CD40;HLA-DRB1;CD86;...
Other types of O-glycan biosynthesis 1.78 1.85e-2 29/47 (61.7%) C1GALT1C1;GALNT3;OGT;...
Ribosome biogenesis in eukaryotes 1.78 1.81e-2 52/108 (48.15%) POP4;NXT1;NOP56;...
Cell cycle 1.73 2.28e-2 110/124 (88.71%) PCNA;CDC20;MCM7;...
Autoimmune thyroid disease 1.67 4.58e-2 46/53 (86.79%) CD40;HLA-DRB1;CD86;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 10uM 6H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 10uM 6H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 10uM 6H, 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
1HAEo- CVCL_0128 Homo sapiens 10uM 24H
NL20 CVCL_0461 Homo sapiens 10uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H, 24H
Normal (Fibroblast)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HFL1 CVCL_4295 Homo sapiens 10uM 24H
IMR-90 CVCL_0347 Homo sapiens 10uM 24H
WI-38 CVCL_0579 Homo sapiens 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 10uM 6H